Clinical Study
Serum Levels of Lipopolysaccharide and 1,3-β-D-Glucan Refer to the Severity in Patients with Crohn’s Disease
Table 1
Demographic characteristics and clinical features of the CD patients.
| | | A-CD ( = 46) | R-CD ( = 22) |
| | Age at diagnosis | | | | A1 (≤16 years) | 6 | 1 | | A2 (17–40 years) | 28 | 14 | | A3 (>40 years) | 12 | 7 | | Gender (male/female) | 28/18 | 17/5 | | Classification | | | | L1 | 3 | 8 | | L2 | 8 | 2 | | L3 | 35 | 12 | | Current smoking | 2 | 3 | | Current treatment | | | | 5-ASA | 14 | 5 | | Azathioprine | 4 | 4 | | Corticosteroids | 12 | 1 | | IFX | 16 | 12 | | Age at CD diagnosis (year) | 33.07 ± 15.70 (12–53) | 35.95 ± 10.65 (16–47) | | Duration (month) | 36.15 ± 40.14 (0.75–168) | 30.14 ± 25.61 (2.0–96) | | LPS (pg/mL) () | 1.19 ± 0.59 (0.30–2.70) | 0.84 ± 0.41 (0.30–1.93) | | BG (pg/mL) () | 2.03 ± 0.74 (0.7–3.00) | 1.39 ± 0.71 (0.48–3.00) | | ESR (mm/h) | 34.39 ± 18.37 (2.0–64) | 21.53 ± 2.97 (7–38) | | CRP (mg/L) | 42.04 ± 41.42 (3.27–157) | 31.06 ± 57.20 (0.5–203) | | CDAI | 194.40 ± 65.71 (39.6–335.80) | 128.36 ± 62.13 (40.20–278.1) | | SES-CD | 9.84 ± 5.59 (2.40–23.40) | 1.11 ± 0.93 (0.00–2.00) |
|
|
5-ASA: 5-aminosalicylate; SD: standard deviation; M/F: male/female; CRP: C-reactive protein; CDAI: CD activity index; SES-CD: simple endoscopic score for CD; TNF: tumor necrosis factor; LPS: lipopolysaccharide; BG: 1,3--D-glucan.
|
